Safety and tolerability of the first-in-class agent CPI-613 in combination with modified FOLFIRINOX in patients with metastatic pancreatic cancer: a single-centre, open-label, dose-escalation, phase 1 trial
Alistar, Angela, Dr, Morris, Bonny B, MSPH, Desnoyer, Rodwige, MD, Klepin, Heidi D, MD, Hosseinzadeh, Keyanoosh, MD, Clark, Clancy, MD, Cameron, Amy, PA, Leyendecker, John, Prof, D'Agostino, Ralph, Prof, Topaloglu, Umit, PhD, Boteju, Lakmal W, PhD, Boteju, Asela R, ASc, Shorr, Rob, PhD, Zachar, Zuzana, PhD, Bingham, Paul M, PhD, Ahmed, Tamjeed, MD, Crane, Sandrine, MD, Shah, Riddhishkumar, MD, Migliano, John J, MD, Pardee, Timothy S, MD, Miller, Lance, PhD, Hawkins, Gregory, PhD, Jin, Guangxu, PhD, Zhang, Wei, Prof, Pasche, Boris, Prof
Published in The lancet oncology (01.06.2017)
Published in The lancet oncology (01.06.2017)
Get full text
Journal Article